RICHMOND, Va. and MONTREAL, Feb. 26, 2014 /PRNewswire/ — Global Genomics Group (G3) and Caprion Proteomics, Inc., today announced that they have entered into a collaboration agreement to investigate biological networks and pathways in order to discover novel biomarkers and pharmaceutical targets for cardiovascular diseases. Under the terms of the agreement, Caprion will identify blood-based protein markers for the GLOBAL (Genetic LOci and Burden of Atherosclerotic Lesions) study. GLOBAL is the largest pan-omic study combining genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics and lipoprotein proteomics with coronary computed tomographic (CT) angiography, an advanced imaging technology for phenotyping, which allows precise disease classification of patients.

Read the full article here: http://www.prnewswire.com/news-releases/global-genomics-group-g3-and-caprion-to-partner-on-global-study-to-identify-cardiovascular-disease-biomarkers-and-drug-targets-247246581.html